ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2019
Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 65 citations in OpenAlex.
- Menopause and neurological disorders: a roadmap for research.Nature reviews. Neurology · 2026Review
- Profiling miRNAs Involved in Human Oligodendrocyte Precursor Cell Differentiation and Maturation.Cells · 2026Article
- Modulation of the unfolded protein response with a C-terminal fragment of MANF facilitates recovery in models of multiple sclerosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Dual-Targeting miR-219 and miR-146a in Multiple Sclerosis: Bridging Myelin Repair and Neuroinflammation for Novel Therapeutic Insights.Cellular and molecular neurobiology · 2026Review
- Bazedoxifene and Beyond: Identifying This SERM's Targets and Deciphering Its Molecular Mechanisms.Advances in pharmacological and pharmaceutical sciences · 2026Review
- The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives.Neuroscience and biobehavioral reviews · 2025Review
- Review
- Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities.Molecular neurodegeneration · 2025Review
- Restore axonal conductance in a locally demyelinated axon with electromagnetic stimulation.Journal of neural engineering · 2025Article
- Rebalancing immunity: The emerging role of selective estrogen receptor modulators in immunity and autoimmunity.Current trends in immunology · 2025Article
- An Overview of Oligodendrocyte Metabolism.Advances in neurobiology · 2025Review
- Exploring the role of sex hormones and gender diversity in multiple sclerosis.Nature reviews. Neurology · 2025Article
- The Role of Estrogen in Brain MicroRNAs Regulation.Advanced pharmaceutical bulletin · 2024Review
- Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings.Cells · 2024Review
- Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data.Current neurology and neuroscience reports · 2024Review
- Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches.Current allergy and asthma reports · 2023Review
- Article
- Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Insights into the mechanism of oligodendrocyte protection and remyelination enhancement by the integrated stress response.bioRxiv : the preprint server for biology · 2023Article
- Remyelination in animal models of multiple sclerosis: finding the elusive grail of regeneration.Frontiers in molecular neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
A significant unmet need for patients with multiple sclerosis (MS) is the lack of U.S. Food and Drug Administration (FDA)-approved remyelinating therapies. We have identified a compelling remyelinating agent, bazedoxifene (BZA), a European Medicines Agency (EMA)-approved (and FDA-approved in combination with conjugated estrogens) selective estrogen receptor (ER) modulator (SERM) that could move quickly from bench to bedside. This therapy stands out as a tolerable alternative to previously identified remyelinating agents and other candidates within this family. Using an unbiased high-throughput screen, with subsequent validation in both murine and human oligodendrocyte precursor cells (OPCs) and coculture systems, we find that BZA enhances differentiation of OPCs into functional oligodendrocytes. Using an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.